Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,341

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Open access
Fraenkel, Liana, Bathon, Joan M., England, Bryant R., St.Clair, E. William, Arayssi, Thurayya, Carandang, Kristine, Deane, Kevin D., Genovese, Mark, Huston, Kent Kwas, Kerr, Gail, Kremer, Joel, Nakamura, Mary C., Russell, Linda A., Singh, Jasvinder A., Smith, Benjamin J., Sparks, Jeffrey A., Venkatachalam, Shilpa, Weinblatt, Michael E., Al‐Gibbawi, Mounir, Baker, Joshua F., Barbour, Kamil E., Barton, Jennifer L., Cappelli, Laura, Chamseddine, Fatimah, George, Michael, Johnson, Sindhu R., Kahale, Lara, Karam, Basil S., Khamis, Assem M., Navarro-Millán, Iris, Mirza, Reza, Schwab, Pascale, Singh, Namrata, Turgunbaev, Marat, Turner, Amy S., Yaacoub, Sally, Akl, Elie A.·2021·Arthritis Care & Research

Abstract

Objective: To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. Methods: We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. Results: The guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional). Conclusion: This clinical practice guideline is intended to serve as a tool to support clinician and patient decision‐making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision‐making process based on patients’ values, goals, preferences, and comorbidities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.24596

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 13

  1. Curtis JR, Real‐world outcomes associated with triple therapy versus tumor necrosis factor inhibitor/methotrexate therapy, Arthritis Care Res (Hoboken)
  2. Pfizer.Pfizer shares co‐primary endpoint results from post‐marketing required safety study of Xeljanz (Tofacitinib) in subjects with rheumatoid arthritis (RA). URL:https://investors.pfizer.com/investor-news/press-release-details/2021/Pfizer-Shares-Co-Primary-Endpoint-Results-from-Post-Marketing-Required-Safety-Study-of-XELJANZ-tofacitinib-in-Subjects-with-Rheumatoid-Arthritis-RA/default.aspx.
  3. 10.1136/annrheumdis-2013-204882 · doi:10.1136/annrheumdis-2013-204882
  4. 10.7326/M16-0713 · doi:10.7326/m16-0713
  5. 10.1136/annrheumdis-2018-213731 · doi:10.1136/annrheumdis-2018-213731
  6. 10.1007/s00296-017-3749-7 · doi:10.1007/s00296-017-3749-7
  7. 10.1002/art.39626 · doi:10.1002/art.39626
  8. 10.1136/bmj.h1389 · doi:10.1136/bmj.h1389
  9. 10.1136/annrheumdis-2014-205726 · doi:10.1136/annrheumdis-2014-205726
  10. 10.1002/art.40196 · doi:10.1002/art.40196
  11. 10.7326/0003-4819-127-5-199709010-00003 · doi:10.7326/0003-4819-127-5-199709010-00003
  12. 10.1002/1529-0131(199807)41:7<1327::AID-ART30>3.0.CO;2-T · doi:10.1002/1529-0131(199807)41:7<1327::aid-art30>3.0.co;2-t
  13. 10.1007/s00296-010-1525-z · DOI

Cited by

See all 1,341

Metadata

Authors
Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., Kremer, J., Nakamura, M. C., Russell, L. A., Singh, J. A., Smith, B. J., Sparks, J. A., Venkatachalam, S., Weinblatt, M. E., Al‐Gibbawi, M., Baker, J. F., Barbour, K. E., Barton, J. L., Cappelli, L., Chamseddine, F., George, M., Johnson, S. R., Kahale, L., Karam, B. S., Khamis, A. M., Navarro-Millán, I., Mirza, R., Schwab, P., Singh, N., Turgunbaev, M., Turner, A. S., Yaacoub, S., & Akl, E. A.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2021-06-08
Volume
73
Issue
7
Pages
924-939
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W3171954900
Cited by
1,341
References
55
FWCI
134.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.